|
Rivus HU6 HFpEF Potential | A Case for HF Specialists
August 15, 2024
|
|
|
|
|
Together with
|
|
|
|
“I think Mr. and Mrs. Rife were destined to be together.”
|
|
UPMC’s Dr. Hemal Gada when after 50 years of marriage, two of his patients were diagnosed with aortic stenosis on the same day, underwent TAVR procedures a week apart, and had “literally identical annular perimeters.”
|
|
|
|
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements – without the risk of muscle loss.
- HU6 is an oral Controlled Metabolic Accelerator that promotes weight loss by making energy production less efficient, forcing the body to rev up metabolism to maintain homeostasis, while avoiding muscle loss.
- The deadly diet pill of the 1930s, DNP, acted through the same pathway but was abandoned because it famously ‘cooked internal organs.’
- Safe to say Rivus has avoided DNP’s safety concerns, and has already raised over $167M to support HU6’s development.
A key step in Rivus’ HU6 development plan is the HuMAIN trial, which gave 66 people with obesity-related HFpEF either HU6 or a placebo, with dosage escalating throughout the 134 day trial.
- The study met its primary endpoint, with HU6 patients achieving targeted body weight reductions.
- HU6 was also well-tolerated, even among these patients with multiple co-morbidities and taking numerous medications.
Perhaps more importantly, the HU6 group achieved a range of obesity and HF-related secondary endpoints, including exercise capacity, quality of life, body composition, cardiac function/structure, and cardiometabolic dysfunction markers (e.g. blood pressure, pulse, glucose control, inflammation, lipid levels, and liver enzymes).
Rivus suggested that these results “strongly support” HU6’s potential to be the first disease-modifying treatment for HFpEF by enabling fat-specific weight loss, while preserving lean muscle mass.
- Enabling weight loss without sacrificing muscle mass would give HU6 a unique advantage versus GLP-1s, which are increasingly showing their ability to improve HF outcomes, but also cause these often-fragile patients to lose muscle.
- Rivus also believes that these results reinforce HU6’s potential to be used in an even broader range of cardiometabolic diseases.
The next steps towards proving HU6’s cardiometabolic potential include the release of the full HuMAIN trial results in September, an ongoing Phase 2 trial focused on MASH patients, and a forthcoming Phase 3 trial further evaluating HU6 in patients with obesity-related HFpEF.
The Takeaway
HU6 has a lot to prove, but these initial results show that it could drive weight loss and cardiometabolic improvements, without sacrificing muscle mass. That’s not something we can say for GLP-1s, bariatric surgery, or even dieting, and it could give HU6 an attractive position in the growing field of obesity-related cardiometabolic treatments.
|
|
|
Catch up on 2024’s Cardiology Coffee Breaks
Join GE HealthCare on a journey to bridge the gaps to connected cardiovascular care with this season’s Cardiology Coffee Breaks. In the time it takes you to finish your coffee, these Coffee Breaks demonstrate how GE’s integrated solutions empower healthcare organizations to provide precision care, achieve operational efficiency, and enhance patient satisfaction.
|
|
Relieving The Burden of Post-Processing
With the advent of advanced imaging technologies like CCTA come added burdens to technologists and diagnostic imaging centers. See how PIA can relieve the burden of post-processing, saving you time while helping your bottom line.
|
|
The Post-Acute Stroke Game Changer
See how Viz Connect solution can optimize your post-acute stroke pathway. The Viz.ai solution allows the cardiology team to promptly receive Neurology referrals to evaluate patients with suspected AFib for cardiac monitoring and reduce their risk of secondary stroke.
|
|
- Heart Failure Specialist Success: When heart failure patients receive care from HF specialists, it has a major impact on their short- and long-term outcomes. That’s from a new JACC study showing that in 227k patients, those who received HF specialist care while admitted to the hospital for HF exacerbation had 8% lower in-hospital mortality and 11% lower risk of death in the long term. Additionally, patients who received HF specialist care were much more likely to be discharged with guideline-directed medical therapy.
- New HF Expert Consensus: In other heart failure news, an update to the ACC Expert Consensus Decision Pathway emphasizes the use of SGLT2 inhibitors throughout hospitalization and underscores the importance of initiating all four pillars of guideline-directed therapy for HFrEF patients post-stabilization. New strategies include alternative diuretics, updated admission criteria, and a greater focus on palliative care to improve long-term outcomes and goal discussions.
- RDN NTAPs: Medtronic and Recor Medical’s first renal denervation systems will see a boost from New Technology Add-on Payments (NTAPs), designed to support the the adoption of emerging medical technologies. The new RDN NTAPs will launch on October 1st and run for three years, covering inpatient procedures performed on Medicare patients, with reimbursements as high as $14,950 for Recor’s Paradise uRDN system. Although renal denervation isn’t typically an inpatient procedure, the NTAPs are a sign of reimbursement progress for the new technology.
- Ambulatory EP Safe: A retrospective study found that cardiac electrophysiology procedures were safely performed at ambulatory surgery centers (ASCs) as part of the pandemic’s Hospital Without Walls program. Among 4,037 ASC procedures, adverse event rates for CIED implantations and catheter ablations (0.76% and 0.73%) matched event rates at hospital outpatient departments (0.65% and 0.80%) where these procedures are usually done.
- Furosemide’s Expanded Approval: scPharmaceuticals received FDA approval to expand FUROSCIX’s (furosemide) indication for treating fluid overload to include NYHA Class IV heart failure patients, the most symptomatic group which represents 10% of all HF cases. The IV loop diuretic was first approved for treating NYHA Class II and III patients in 2022, and has shown to be effective in reducing heart failure-related hospitalizations since then.
- RPM + CCM = Improved Outcomes: New research on 42k patients using HealthSnap’s remote patient monitoring portals demonstrated the positive cardiometabolic impact of integrating remote patient monitoring with chronic care management. Hypertensive patients enrolled in the program for over 90 days saw an average SBP reduction of 23.8 mmHg and DBP reduction of 14.5 mmHg, while type 2 diabetics with severe hyperglycemia (≥180 mg/dL) achieved an impressive 56.8 mg/dL improvement (vs. ~40-60 mg/dL for common non-insulin medications like Metformin and GLP-1s).
- Siemens Cardiac Echo Cleared: Siemens Healthineers announced the FDA clearance of its AI-powered Acuson Origin cardiovascular ultrasound scanner, and related AcuNav Lumos 4D ICE catheter. The Acuson Origin system targets a range of clinical settings, including pediatric, structural heart, vascular, and EP exams, while its AI applications support automated TTE and TEE measurements and automated contouring and quantification of all four cardiac chambers (without requiring ECG).
- SGLT2is Vastly Underused: Many patients who are eligible for SGLT2is based on Class 1a guideline criteria are missing out on the drugs. In a study of 2022-2023 Optum Labs data featuring more than 3M patients in 28 health systems, 63.4% of those with diabetes (n=716k) met Class 1a criteria but only 11.9% got SGLT2i prescriptions, while 6.2% of patients without diabetes met Class 1a criteria but only 3.1% were prescribed an SGLT2i.
- Novartis’ Entresto Generic Setback: Novartis hit another setback in its efforts to block Entresto generics, after a Delaware District Judge rejected Novartis’ infringement claims against MSN Laboratories and denied its request to halt MSN’s generic launch. The judge expressed his skepticism that the generic would harm Novartis, although a wave of generics certainly wouldn’t be good for the $6B HF drug. Because of that, Novartis’ legal team has been actively fighting Entresto generics, including another MSN-focused lawsuit last week against the FDA.
- AI Appears Safe: The number of FDA AI approvals is growing, but how safe are the AI products that are getting onto the market? A new analysis by legal expert Bradley Merrill Thompson examining medical device reports (MDRs) submitted to the FDA (typically filed when something goes wrong) suggests that these AI solutions are pretty safe. Thompson compared MDRs filed for AI/ML-enabled devices with filings for all other medical devices, finding that “AI devices are currently producing fewer MDRs than the medical device universe in general.”
- Zymedi’s PAH ODD: Zymedi’s ZMA001 monoclonal antibody candidate scored FDA Orphan Drug designation for the treatment of pulmonary arterial hypertension, potentially supporting Zymedi’s development and commercialization efforts. ZMA001 inhibits macrophage-induced inflammation in the lungs, thus inhibiting PAH symptoms from the early stages. ZMA001 has shown superior efficacy versus existing PAH drugs in preclinical studies, and has shown “a synergistic effect” when used in tandem with other treatments.
|
|
Merge and Duly Health Streamline Cardiology Reporting
Over the last 10 years, Dr. Sujith Kalathiveetil of Duly Health and Care has seen a significant evolution in cardiovascular imaging and experienced a similar evolution with Merge’s cardiology solutions. See how Merge Cardio has helped make cardiology reporting more consistent, accurate, and easier to obtain for Dr. Kalathiveetil and his colleagues.
|
|
Incidental CAC Predicts Long-Term Risks
What if you could identify which of your asymptomatic patients have high risks of future cardiac events? Stanford-led researchers used Bunkerhill Health’s Incidental CAC algorithm to do just that, finding that patients with ≥100 incidental CAC scores had a 24% 10-year risk of developing ASCVD and far higher risks of major adverse events.
|
|
Tracking Your Post-Treatment Plaque
Tune-in to this on-demand Cleerly webinar where preventative cardiologist John Osborne, MD, PhD, FACC, FNLA explores how to use CTA to track plaque progression and identify residual risk post-treatment.
|
|
- Echo AI for HFpEF: New research comparing Us2.ai to gold-standard invasive hemodynamic measurement showed that in patients with HFpEF, echo AI measurements are interchangeable with manual core-lab measures to diagnose increased filling pressures – and could improve HFpEF detection.
- Experience the future of learning: Medtronic Academy 2.0 is here! Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
- An All-in-One Coronary Care Solution: See how HeartFlow ONE is transforming precision heart care as the first all-in-one CCTA pathway, combining FFRCT, stenosis, and plaque analysis in a single workflow.
- Structured Reporting Cuts Late Charges: Structured reporting is often associated with efficiency improvements, but its ability to reduce errors and improve billing accuracy can deliver benefits across a cardiovascular service line. See how Baystate Medical Center’s transition to structured cardiology reporting with Optum helped them reduce unsigned charges by 79%.
- Explore the Potential of Cardio AI: Explore the potential of AI-powered cardiology solutions in this on-demand TeraRecon webinar, detailing how its Cardio Suite solutions help expedite disease diagnosis, care coordination, and provide the data to support cardiac treatment decisions.
- Assessing CAD with Circle CVI: Did you know that Circle CVI offers a suite of cardiac CT tools for the assessment of coronary artery disease? See how Circle combines heart function segmentation, automated plaque analysis, CAC scoring, reporting, and viewing in a single dedicated Cardiac CT package.
- Accurate and Efficient Remote Cardiac Patient Monitoring: The expansion of remote cardiac patient monitoring is creating more care opportunities, but also new operational challenges for cardiology teams. Check out this Cardiac Wire Show, where ARTELLA Solutions’ Jacinta Fitzsimons shares how the right combination of technology and service can help physicians get the most out of their cardiac RPM programs – today and into the future.
|
|
|
|
|
